rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Eikon Therapeutics, Inc.

EIKN · Nasdaq

Health CareBiotechnology

We hold no 150-day reading for EIKN yet: it needs about 200 sessions of history. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
not in the set
Weeks in an uptrend
—
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$104.3M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
75 (+26)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$98.6MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months10
Sale orders, 12 months0
Buyers · sellers9 · 0
WhoDidSharesTraded
Column Group Iv Gp, Lp10% ownerbought89,200at $11.563 Sep 2026filed 8 Sep 2026
Column Group Iv Gp, Lp10% ownerbought1,437,323at $18.006 Feb 2026filed 9 Feb 2026
Column Group Iv Gp, Lp10% ownerbought49,556at $18.006 Feb 2026filed 9 Feb 2026
Column Group Iv Gp, Lp10% ownerbought630,881at $18.006 Feb 2026filed 9 Feb 2026
Foresite Capital Management Iv, Llc10% ownerbought55,555at $18.004 Feb 2026filed 6 Feb 2026
Lux Venture Partners V, Llc10% ownerbought138,888at $18.004 Feb 2026filed 6 Feb 2026
Lux Venture Partners V, Llc10% ownerbought138,888at $18.004 Feb 2026filed 6 Feb 2026
Josh WolfeDirector, 10% ownerbought138,888at $18.004 Feb 2026filed 6 Feb 2026
Josh WolfeDirector, 10% ownerbought138,888at $18.004 Feb 2026filed 6 Feb 2026
Kenneth C. FrazierDirectorbought111,111at $18.004 Feb 2026filed 6 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders75+26 on the quarter
New · exited38 · 12
Reported value$312.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 20264,993,906$65.2M+1,157,076+30.2%
BlackRock, Inc.added · filed 7 Aug 20264,281,425$55.9M+962,046+29.0%
Foresite Capital Management IV, LLCunchanged · filed 14 Aug 20261,943,682$25.4M00.0%
Merck & Co., Inc.unchanged · filed 7 Aug 20261,666,666$21.7M00.0%
Foresite Capital Management V, LLCunchanged · filed 14 Aug 20261,318,983$17.2M00.0%
Capital World Investorsadded · filed 12 Aug 20261,175,944$15.3M+32,307+2.8%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026922,707$12.0M-46,724−4.8%
EcoR1 Capital, LLCunchanged · filed 14 Aug 2026732,606$9.6M00.0%
ALLIANCEBERNSTEIN L.P.reduced · filed 14 Aug 2026641,888$6.8M-380,300−37.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026556,955$7.3M+283,024+103.3%

Everyone who traded it

Column Group IV GP, LP Company insider10% owner · last 3 Sep 20262 · 0
Tim Kutzkey Company insider10% owner · last 3 Sep 20261 · 0
Alfred Lloyd Bowie Jr. Company insiderChief Financial Officer · last 2 Mar 20260 · 0
Benjamin Bruno Thorner Company insiderOfficer · last 2 Mar 20260 · 0
Kenneth C. Frazier Company insiderDirector · last 2 Mar 20261 · 0
Michael A. Klobuchar Company insiderChief Operating Officer · last 2 Mar 20260 · 0
Robert Luther Huffines Company insiderDirector · last 2 Mar 20260 · 0
Roger M. Perlmutter Company insiderSee remarks · last 2 Mar 20260 · 0
Roy D. Baynes Company insiderChief Medical Officer · last 2 Mar 20260 · 0
Column Group Opportunity Iii, Lp Company insider10% owner · last 6 Feb 20261 · 0
Josh Wolfe Company insiderDirector, 10% owner · last 6 Feb 20261 · 0
Lux Venture Partners V, LLC Company insider10% owner · last 6 Feb 20261 · 0

Same industry

No other stock in its industry this week.

Government contracts

No federal award is tied to it.

From its SEC filings

No ratio computed from its SEC filings yet.

Analyst forecasts

No analyst forecasts yet.